PEPTIDES TARGETED AT DLL3 AND ITS CONSTRUCTS

PE0013282026A1Pending Publication Date: 2026-07-09MARIANA ONCOLOGY INC

View PDF 0 Cites 0 Cited by

Patent Information

Application Number: PE2025003098
Authority / Receiving Office: PE · PE
Patent Type: Applications
Current Assignee / Owner
Priority Date: 2024-06-13
Filing Date: 2024-06-13
Publication Date: 2026-07-09

Application Information

Patent Timeline

13 Jun 2024

Priority

13 Jun 2024

Application

PE2025003098

09 Jul 2026

Publication

PE0013282026A1

IPC: A61P35/00; A61K38/00; A61K51/08; C07K7/08; C07K14/47

CPC: A61K51/088; C07K7/08; A61P35/00; C07K14/4748; C07K7/64; A61K51/0482; A61K2121/00; C07K14/001

Inventors: METCALF III Chester A.; HUANG Chunhui

Get more patent work done with AI

Run novelty searches—or use them for FTO, design risk, drafting and technical problem-solving.

Explore More Agents

Novelty Search
Search existing technologies and assess novelty
↗
FTO
Analyze whether a product may infringe others' patents
↗
Design FTO
Check prior-design risk for exterior design
↗
Drafting
Draft patent application text based on a technical solution
↗
Find Solutions with TRIZ
Generate feasible solution to solve your technical challenge
↗
IP MCP Servers
Connect trusted patent search and cited evidence to Claude, Cursor or your own AI workflow
↗

Patent Text Reader

Abstract

The present invention relates to cyclic peptides and to a pharmaceutical composition comprising the peptide or one of its pharmaceutically acceptable salts. The peptide, its salts, or the pharmaceutical composition enables the treatment of DLL3-mediated cancers, such as small cell lung cancer, urothelial cancer, neuroendocrine neoplasia, and other types of cancer.

Need to check novelty before this filing date? Find Prior Art